EML4-ALK positive lung cancer is a medical term that refers to a primary malignant lung tumor whose cells contain a characteristic abnormal configuration of DNA wherein the echinoderm microtubule-associated protein-like 4 (EML4) gene is fused to the anaplastic lymphoma kinase (ALK) gene.
cancer | American Cancer Society | breast cancer | National Cancer Institute | Cancer Research UK | Cancer | Memorial Sloan-Kettering Cancer Center | Hau Lung-pin | Fred Hutchinson Cancer Research Center | colorectal cancer | Tropic of Cancer | prostate cancer | National Heart, Lung, and Blood Institute | Macmillan Cancer Support | lung | Ludwig Institute for Cancer Research | liver cancer | Fox Chase Cancer Center | Colorectal cancer | American Lung Association | Teenage Cancer Trust | Princess Margaret Cancer Centre | International Agency for Research on Cancer | Esophageal cancer | Breast Cancer Care | Breast Cancer | Union for International Cancer Control | Tropic of Cancer (novel) | Stay Positive | Positive K |
ALK inhibitors are potential anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation.
About 4% of patients with non-small cell lung carcinoma have a chromosomal rearrangement that generates a fusion gene between EML4 ('echinoderm microtubule-associated protein-like 4') and ALK ('anaplastic lymphoma kinase'), which results in constitutive kinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype.